Annual Submission of Compliance Information for Electromedical Devices

1. Key takeaways

South Africa imposes an Annual Submission of Compliance Information (ASOCI) requirement on establishment licence holders of imported electromedical devices. The mechanism works as follows: licence holders are divided into 8 alphabetical groups, and notifications are sent out by e-mail in monthly batches starting from 1 April each year; companies must submit the completed compliance information form within 30 working days of receiving the notification, and the SAHPRA processing window is 60 working days. This is an annual obligation that is independent of the annual retention fee, and it targets only specific product categories. Companies that import electromedical equipment should therefore treat ASOCI as a fixed feature of their yearly compliance calendar, identify their alphabetical group in advance, and make sure that both the notified e-mail address and a responsible person are reachable throughout the relevant months, because the notification window does not wait for anyone.

2. Legal basis

3. Expert insights

Insight one: ASOCI is a South African-specific compliance check-up that rolls forward by alphabetical group. The design of 8 alphabetical groups combined with monthly notifications starting from 1 April spreads the workload across the year. This means different companies have different submission windows — a company must know which group it belongs to and maintain reachability of its e-mail contacts and responsible staff in the assigned month. Missing the group window because nobody was watching the mailbox is the most avoidable of all ASOCI failures, yet it is also the most common one described in practice.

Insight two: the two timelines bind the company and SAHPRA respectively, and they are different in nature. The 30 working days is the company’s submission deadline; the 60 working days is SAHPRA’s processing window. The former is an obligation, the latter is a service commitment. A company can only control the former, and there is no described statutory grace mechanism for missing it, so internal deadlines should be set well inside the official one.

Insight three: ASOCI targets imported electromedical devices, not all devices. The scope of the obligation is limited to imported electromedical devices. Pure consumables, IVD reagents and non-electrical devices are in principle outside the scope (a practical estimate, to be confirmed against SAHPRA’s actual notification). Companies should first confirm whether they are among the notified parties at all, to avoid both pointless preparation and accidental non-submission. The confirmation itself should be recorded, so that the decision not to submit is documented if the question is ever raised later.

Insight four: ASOCI and the annual retention fee are two independent obligations. The retention fee is a financial obligation (payable before June each year); ASOCI is an information obligation (submission of the compliance information form according to the assigned group). They do not substitute for each other, and their timing differs — the compliance register must manage them separately, with distinct owners, reminders and evidence files, so that paying the fee is never mistaken for having satisfied the information duty.

Insight five: ASOCI shares a compliance thread with radiation control and R1302. Electromedical devices typically involve both electrical safety and, where they emit radiation, radiation control. The practical estimate is that companies can consolidate electrical safety certificates, radiation control licence status and CE certificate validity into a single compliance dossier that serves ASOCI and the other annual confirmation obligations at the same time — one preparation, many uses.

4. Practical recommendations

1. Confirm whether the company is an ASOCI notification addressee: the scope is imported electromedical devices.
2. Confirm the alphabetical group and the expected notification month: prepare materials in advance.
3. Set a 30-working-day submission reminder: start upon receipt of the notification, not at the end of the window.
4. Manage ASOCI separately from the annual retention fee: the obligations differ in nature and timing.
5. Consolidate the electrical safety and radiation compliance dossier: prepare once, use many times.
6. Retain submission evidence and SAHPRA acknowledgements.

5. Verification checklist

• □ It has been confirmed whether the company imports electromedical devices (the ASOCI scope)
• □ The alphabetical group (8 groups) and expected notification month have been confirmed
• □ A submission reminder has been set for the 30 working days after notification
• □ The compliance information form template has been prepared in advance
• □ ASOCI and the annual retention fee are managed separately
• □ The electrical safety, CE validity and radiation control status dossier has been consolidated
• □ Submission evidence and SAHPRA acknowledgements have been archived
• □ The SAHPRA processing window of 60 working days has been confirmed

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above as published on that date; where official documents have been updated, the most recently published version prevails.

• Local resources in South Africa: GRZAN assists manufacturers from the Chinese mainland and other markets with SAHPRA medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation, and the setup of vigilance and adverse event notification mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A, B, C, D), establishment licence applications and renewals, reliance pathway argumentation, technical documentation and essential principles conformity argumentation, labelling and instructions for use localisation in English, and support for post-market vigilance and annual compliance submissions.
• Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.